Why the use of cancer data is so important, and why the current model is so valuable



Cancer Research UK Cancer Survival Group

National Consent Model Workshop London, 21 April 2016



"One overarching goal"

There will be major reductions in premature deaths from cancer, and improvements in quality of life and cancer survival.

www.uicc.org/world-cancer-declaration, 25 November 2013

Private autonomy vs. public interest

How do we balance the individual's right to privacy with society's right to understand the health risks we all face, and how effectively those risks are being controlled? Data protection and sharing for research

Potential risks Societal benefits Threats to data sharing for research A way forward ...

Use of identifiable data: public interest Risks and benefits

Potential risk to individuals Some loss of autonomy Very low risk of breach of confidentiality

Proven benefit to individuals *and* society Causes of cancer – prevention Incidence – planning Survival – effectiveness of health system Survivorship – quality of life, rehabilitation, care

The individual and society

From the general to the particular Search data about individuals to select someone for action (tax, arrest, ...)

From the particular to the general Analyse data about individuals to inform society, but not to identify any person



Population-based cancer registry

Attempts to record information on all new cases of cancer in a defined population

Person:	habitual resident
Place:	defined territory
Time:	continuous

"...the most valuable data are, undoubtedly, the rates obtained by the occurrence of *every* case of cancer over a specified period"

Doll et al. Cancer Incidence in Five Continents Vol. 1. 1966

A registry "records all new cases of cancer in a defined population"

Jensen et al. Cancer Registration: Principles and Methods, 1991

Measures of cancer burden – definition

- Incidence new cases (number, rate)
- Survival probability alive at time "t"
- Prevalence survivors (number, %)
- Mortality deaths (number, rate)

Measures of cancer burden – for me

- Incidence what's my risk?
- Survival what are my chances?
- Prevalence how many of us are there?
- Mortality those we have lost ...

Measures of cancer burden - application

- Incidence prevention, planning
- Survival effectiveness of health care
- Prevalence care, survivorship
- Mortality priorities



Cancer in Europe 2002-2020		
Annual change in incidence rates	New cases per year	Increase from 2002
No change	3,300,000	+ 20 %
1% rise	4,000,000	+ 40 %
2% rise	4,800,000	+ 70 %
		Bray, 2008



Clinical research and public health		
Clinical trials	highest <i>achievable</i> survival	
Public health	average survival achieved	
Translational research to reduce the difference		





Use of identifiable information in cancer registration is *unavoidable*

- · Quality assurance (validity)
- Eliminate duplicates (inflation of incidence)
- Clinical data not routinely captured (scope)
- Linkage of events (cause, outcome)
- Assessment of survival
- Small area analyses (clusters)
- Assessment of genetic risks
- Surveillance, audit and research

Opt-out from registries will not work Unquantifiable loss of information

- Most patients would consent, some would not
- Many patients would not be asked
- Complete, unbiased coverage would be lost
- True disease burden would be unknown
- Comparisons would become unreliable:
- time, geographic area, population sub-group
- Projections of future burden unreliable
- Health inequalities no longer reliably measured

Can governments formulate rational policy without key indicators ?

Policy-makers would be "flying blind"

- Policy-vital information: unreliable or unavailable
- Burden of new cancers: unknown Age, sex, region, population sub-groups ...
- Future projections: unreliable
- · Health inequalities: not reliably measured

Informed consent will not work No effective cancer registry with informed consent

- West Germany informed consent, 1990 Hamburg and Saarland registries closed for 2 years
 East Germany informed consent, 1990-
- Closure of largest European cancer registry (1953-)
 Hungary Personal Data Protection Act 1992
- Cancer registration stopped until 1999
 UK General Medical Council guidance 2000
 - Emergency legislation required to protect registries
- Nordic countries statutory, no consent
 Efficient, complete, productive cancer registries

The "principle" of informed consent in public health

"I doubt whether informed consent can be a feasible general principle in public health. It is the fundamental principle in clinical ethics, in the clinical encounter. It never has been the fundamental principle in public health, where we have always had to look to other principles of legitimation."

Baroness O'Neill of Bengarve. Health Service Regulations 2002. Lords Hansard 21 May 2002: c746-7

UK survey of public attitudes

- Heard of National Cancer Registry 17% yes
- Screening invitation invades privacy 96% no
- Postcode in Registry invades privacy 89% no
- Invitation for research invades privacy 88% no
- Support law on cancer registration 83% yes

Barrett et al., Br Med J 2006

Messages for the media ...

- Medical records are vital for research
- Identifiable data are used anonymously
- Unblemished record on confidentiality
- Vast, beneficial medical research output
- Confidential research is in everyone's interest
- Medical research is *already* being prevented

The Government should...

- Explain to the public why, despite the underlying principle of consent for data collection, identifiable data must for some purposes be collected without consent, for research that harms no-one and benefits everyone.
- Make cancer registration a statutory requirement

Medical research is threatened by insistence on patient consent

"I don't expect patients just to tolerate the kind of work that cancer registries and epidemiologists do: I believe they would be astonished if it weren't done."

Ben Traynor Consenting adults Guardian 12 April 2001



Margaret Grayson speaks in Belfast, June 2015